US20250228796A1 - Skeletal muscle enhancer - Google Patents

Skeletal muscle enhancer

Info

Publication number
US20250228796A1
US20250228796A1 US18/849,050 US202318849050A US2025228796A1 US 20250228796 A1 US20250228796 A1 US 20250228796A1 US 202318849050 A US202318849050 A US 202318849050A US 2025228796 A1 US2025228796 A1 US 2025228796A1
Authority
US
United States
Prior art keywords
muscle
skeletal muscle
atrophy
skeletal
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/849,050
Other languages
English (en)
Inventor
Kazumasa Okubo
Yoshiki Itoh
Masaya Nakamura
Osahiko Tsuji
Keisuke Horiuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sato Pharmaceutical Co Ltd
Keio University
Original Assignee
Sato Pharmaceutical Co Ltd
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sato Pharmaceutical Co Ltd, Keio University filed Critical Sato Pharmaceutical Co Ltd
Assigned to SATO PHARMACEUTICAL CO., LTD., KEIO UNIVERSITY reassignment SATO PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ITOH, YOSHIKI, OKUBO, KAZUMASA, HORIUCHI, KEISUKE, TSUJI, OSAHIKO, NAKAMURA, MASAYA
Publication of US20250228796A1 publication Critical patent/US20250228796A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the homeostasis of skeletal muscle is controlled by a synthesis system and a degradation system (Non Patent Literature 1). If the maintenance of homeostasis fails and the degradation system becomes dominant, a decrease in skeletal muscle mass (hereinafter, also referred to as “muscle atrophy”) occurs.
  • Non Patent Literature 2 The muscle atrophy that frequently occurs in the elderly due to aging is also called sarcopenia (Non Patent Literature 2). If sarcopenia is developed and muscle atrophy progresses in the whole body, activities of daily living decrease and care and support are required, and thus sarcopenia is a major problem in an aging society. Further, sarcopenia is considered as one cause of chronic low back pain (Non Patent Literature 11).
  • Disuse muscle atrophy occurs due to plaster casting for treatment of a bone fracture caused by injury or osteoporosis, prolonged bed rest (bedridden) due to aging, or the like.
  • Tirm63 (MuRF1) is a representative muscle-specific ubiquitin ligase involved in muscle atrophy, and it has been reported that muscle atrophy is suppressed by depletion of its expression (Non Patent Literature 3).
  • Non Patent Literature 10 muscle strain caused by blunt external force (bruise) is the most frequent sports injury (Non Patent Literature 10). Although there are no accurate statistics, it is considered that the number of patients in Japan is about several tens of thousands per year.
  • the skeletal muscle enhancer according to the present invention can enhance skeletal muscle.
  • FIG. 3 shows the effect on Trim63 gene expression by SPD administration to the muscle atrophy model.
  • FIG. 4 shows the effect on Mstn gene expression by SPD administration to the muscle atrophy model.
  • FIG. 5 shows the effect on skeletal muscle weight by SPD administration to the muscle damage model.
  • FIG. 6 shows the effect on the regenerated muscle area by intramuscular (i.m.) administration of SPD to the muscle damage model.
  • FIG. 7 shows the effect on the regenerated muscle area by intraperitoneal (i.p.) administration of SPD to the muscle damage model.
  • Skeletal muscle enhancers used in drug therapy are suitable for treatment of subjects having difficulty in exercise therapy, particularly, subjects having muscle atrophy due to aging (sarcopenia), muscle atrophy due to disuse muscle atrophy, muscle damage due to external force (in particular, muscle strain (pulled muscle)), or muscle damage due to myogenic disease.
  • the concentration of spermidine or a salt thereof in a skeletal muscle enhancer can be appropriately set depending on the degree of muscle atrophy, muscle damage, and the like.
  • the skeletal muscle enhancer is administered intramuscularly into skeletal muscle. Intramuscular administration exerts a higher effect than other administration routes.
  • the pharmaceutical formulation for intramuscular administration may contain a pharmaceutically acceptable solvent or diluent in addition to an active ingredient.
  • the injection may be prepared in the form of pre-dissolved active ingredient, and further may be prepared in the form that is dissolved at the time of use as a powder of the active ingredient as it is or a powder of the active ingredient added with an appropriate carrier.
  • the injection can contain, for example, 0.005 to 25% by mass of an active ingredient based on the total mass of the pharmaceutical formulation.
  • Spermidine and salts thereof can treat muscle atrophy and muscle damage by enhancing skeletal muscle. Accordingly, the skeletal muscle enhancer according to the present invention can be grasped also as a therapeutic agent for atrophy or damage of skeletal muscle.
  • the description about the active ingredient and formulation of the skeletal muscle enhancer is applied to the therapeutic agent.
  • Spermidine and salts thereof can restore homeostasis inclined to the degradation side in muscle atrophy by suppressing the degradation system or promoting the synthesis system. Accordingly, the skeletal muscle enhancer according to the present invention can be grasped also as a skeletal muscle homeostasis restoring agent.
  • the description about the active ingredient and formulation of the skeletal muscle enhancer is applied to the restoring agent.
  • the left hindlimb of the mouse in a bent state was fixed with a surgical stapler (Kaiser Plus. KEISEI MEDICAL INDUSTRIAL CO., LTD.).
  • the right hindlimb of the same mouse was assigned to the sham-treatment side, and no fixation treatment was performed.
  • the tibialis anterior muscle one of skeletal muscles was collected by dissection. The sample collected after 3 days was supplied to the expression analysis of the muscle atrophy-related genes, and the sample collected after 7 days was supplied to the measurement of a muscle weight and the preparation of a muscle tissue section.
  • the extracted RNA was recovered with 2-propanol and 75% ethanol, and then subjected to the reverse transcription reaction (using ReverTra Ace qPCR RT Master Mix (Toyobo Co., Ltd.) according to the attached protocol) to synthesize cDNA.
  • Tirm63 has been reported to suppress muscle atrophy by depletion of its expression (Non Patent Literature 3), and is a gene that acts on enhancement of the degradation system in the homeostasis of skeletal muscle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US18/849,050 2022-03-22 2023-03-22 Skeletal muscle enhancer Pending US20250228796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022045904 2022-03-22
JP2022-045904 2022-03-22
PCT/JP2023/011182 WO2023182342A1 (ja) 2022-03-22 2023-03-22 骨格筋増強剤

Publications (1)

Publication Number Publication Date
US20250228796A1 true US20250228796A1 (en) 2025-07-17

Family

ID=88101118

Family Applications (1)

Application Number Title Priority Date Filing Date
US18/849,050 Pending US20250228796A1 (en) 2022-03-22 2023-03-22 Skeletal muscle enhancer

Country Status (4)

Country Link
US (1) US20250228796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4497435A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023182342A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023182342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025070707A1 (cg-RX-API-DMAC7.html) * 2023-09-29 2025-04-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998015A (ja) * 1982-11-27 1984-06-06 Microbial Chem Res Found 免疫賦活剤
EP1075254A2 (en) * 1998-04-03 2001-02-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
US9144601B2 (en) 2011-09-15 2015-09-29 Seikagaku Corporation Skeletal muscle regeneration promoter
CA3086250A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using a combination of autophagy inducer and high protein for induction of autophagy
JP7742026B2 (ja) * 2020-04-03 2025-09-19 三菱瓦斯化学株式会社 筋肉増強剤

Also Published As

Publication number Publication date
WO2023182342A1 (ja) 2023-09-28
EP4497435A4 (en) 2025-08-13
EP4497435A1 (en) 2025-01-29
JPWO2023182342A1 (cg-RX-API-DMAC7.html) 2023-09-28

Similar Documents

Publication Publication Date Title
TWI477273B (zh) 低頻率格拉替雷(glatiramer)醋酸鹽之治療
EP3718561A1 (en) Therapeutic agent for inflammatory bowel disease
JP5340941B2 (ja) 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用
JP2007197463A (ja) 筋痙攣およびそれに関連する疼痛を除去するための注射療法
JP2010504083A5 (cg-RX-API-DMAC7.html)
US20250017976A1 (en) Using autologous mesenchymal stem cells to treat multiple system atrophy
EP4497435A1 (en) Skeletal muscle enhancing agent
Goldspink et al. Growth factors, muscle function and doping
AU2019365117B2 (en) Sildenafil for use in the treatment of osteoarthritis
AU2019368245A1 (en) Next generation synthetic transcription factors
US9084761B2 (en) Use of interleukin-15 to treat cardiovascular diseases
CN114555630A (zh) 用于治疗脊髓损伤和/或髓鞘再生的肽的全身施用
US20200031873A1 (en) Repurposing cell penetrating peptides and their novel derivatives and iopromide and iodo-aryl carbonates for treatment of senescence-related diseases and disorders
Limback et al. A comprehensive review of Duchenne muscular dystrophy: genetics, clinical presentation, diagnosis, and treatment
JP2023526249A (ja) うつ病の処置
WO2020201444A1 (en) Repurposing small molecules for senescence-related diseases and disorders
CN118021978A (zh) 用于治疗结节病的方法的ghrh拮抗剂
US20240293441A1 (en) New therapeutic use of type 2 iodothyronine deiodinase (d2) inhibitors
US20120225821A1 (en) Composition for preventing or treating a spinal cord injury
CN112587662A (zh) 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用
WO2018027149A1 (en) Methods of treating alport syndrome
HK40060509B (en) Combination comprising sildenafil for use in the treatment of osteoarthritis
HK40060509A (en) Combination comprising sildenafil for use in the treatment of osteoarthritis
JP2024020797A (ja) 筋萎縮の治療剤
Andre Exploring fibrosis in muscular dystrophy through modulation of the TGF-beta pathway

Legal Events

Date Code Title Description
AS Assignment

Owner name: SATO PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OKUBO, KAZUMASA;ITOH, YOSHIKI;NAKAMURA, MASAYA;AND OTHERS;SIGNING DATES FROM 20240530 TO 20240605;REEL/FRAME:068644/0973

Owner name: KEIO UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OKUBO, KAZUMASA;ITOH, YOSHIKI;NAKAMURA, MASAYA;AND OTHERS;SIGNING DATES FROM 20240530 TO 20240605;REEL/FRAME:068644/0973

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION